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Background
The V3 loop is a major neutralizing determinant of the
HIV-1 virus. Cholera toxin subunit B (CTB) is a highly
immunogenic protein and it has been used in fusion con-
structs to enhance immunogenicity of target proteins. We
hypothesized that a rationally designed immunogen,
based on V3 and CTB, could induce high titers of Abs with
binding mode and epitope specificity similar to known
broadly neutralizing anti-V3 mAbs.
Methods
We used molecular modeling and available crystallo-
graphic structures of the V3 loop in the HIV-1 gp120 con-
text, the V3 loop fragment bound to broadly neutralizing
mAbs, as well as the structure of the CTB to design two
novel V3-scaffold immunogen constructs: a full-length
V3-CTB presenting the complete 35 amino-acid residue
V3 loop in a structural context mimicking the V3 in
gp120, and a short V3-CTB presenting a smaller segment
of V3 in the conformation recognized by mAb 447-52D.
Results
Antigenic properties were evaluated on a panel of 24 anti-
V3 human mAbs. The full V3 construct was recognized
with high affinity by the large majority of mAbs, with
some preference by mAbs derived from clade B-infected
individuals. Short V3 construct exhibited high affinity
binding to mAb 447-52D and only a few additional
mAbs. Immunogenicity of the constructs was evaluated in
rabbits using a DNA prime/protein boost protocol. Boost-
ing with the full-length V3-CTB resulted in serum anti-V3
titers that neutralized multiple HIV virus strains from var-
ious HIV-1 clades. Short V3-CTB construct was ineffective
in boosting the Ab
Conclusion
The results suggest that while (1) a scaffold immunogen
that presents a single epitope (designed to fit a single
mAb) may result in a poor Ab response, (2) focusing the
immune response on a specific immunogenic region,
such as the V3 loop, can elicit a robust Ab response, and
(3) the CTB scaffold can efficiently present V3
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P179 doi:10.1186/1742-4690-6-S3-P179
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P179
© 2009 Totrov et al; licensee BioMed Central Ltd. 